Simulations Plus
About Simulations Plus
Simulations Plus is a specialized software company in pharmacometrics, ADMET prediction, and PK/PD modeling used to simulate drug behavior in humans. The trend reflects growing adoption of advanced in silico modeling in drug development, regulatory science, and personalized medicine to accelerate timelines and reduce costs.
Trend Decomposition
Trigger: Increasing demand for predictive pharmacology to de risk drug development and optimize dosing.
Behavior change: More pharma companies and CROs perform early stage in silico pharmacokinetic/pharmacodynamic analyses and integrate simulation outputs into decision making.
Enabler: Access to validated modeling platforms (e.g., GastroPlus, ADMET Predictor) and growing acceptance by regulators and sponsors.
Constraint removed: Reduced need for costly and lengthy in vivo experiments for initial candidate screening and dose selection.
PESTLE Analysis
Political: Regulatory agencies increasingly emphasize model informed drug development to streamline approvals.
Economic: Cost pressures in drug development drive investment in predictive modeling to shorten timelines and de risk programs.
Social: Stakeholders expect faster access to therapies and more personalized dosing insights through simulations.
Technological: Advances in computing power, machine learning integration, and validated PK/PD models enable more robust simulations.
Legal: More robust data provenance and model validation standards are shaping how simulations are used in submissions.
Environmental: Indirect impact through reducing animal testing and enabling greener, more efficient development pathways.
Jobs to be done framework
What problem does this trend help solve?
It helps reduce discovery risk and accelerate appropriate dosing strategies in drug development.What workaround existed before?
Heavier reliance on empirical in vivo studies and trial and error dose finding.What outcome matters most?
Speed and certainty in predicting human PK/PD and optimizing dose regimens.Consumer Trend canvas
Basic Need: Reliable, usable modeling tools to forecast human drug behavior.
Drivers of Change: Validation of simulation platforms, regulatory interest in model informed development, and cost pressures.
Emerging Consumer Needs: Transparent model governance, reproducibility, and easier integration with data workflows.
New Consumer Expectations: Faster decision cycles and higher confidence in preclinical to clinic transitions.
Inspirations / Signals: Regulatory guidances endorsing modeling, successful case studies, and platform interoperability.
Innovations Emerging: Hybrid modeling with AI assisted parameterization and cloud based collaboration.
Companies to watch
- Simulations Plus - Specializes in pharmacokinetic/pharmacodynamic modeling and simulation software like GastroPlus and ADMET Predictor.
- Certara - Leader in model informed drug development with platforms for PK/PD modeling and simulation.
- Schrödinger - Provides computational chemistry and drug discovery software used for predictive modeling and simulations.
- BIOVIA (Dassault Systèmes) - Offers modeling, simulation, and data management tools for life sciences research.
- Certara's Simcyp - Widely used population PK/PD modeling platform within Certara’s suite.
- Pharmaron - Contract research organization providing integrated drug discovery and development services, including modeling support.
- SIMULIA (Dassault Systèmes) - Engineering focused simulation suite that increasingly supports life sciences workflows.
- Compugen - Biotech analytics company involved in computational research and drug discovery tooling.
- Cygni - Life sciences software firm offering modeling and simulation related services.
- VxBiosciences - Emerging player providing PK/PD modeling and simulation platforms.